The National Medical Products Administration has accepted clinical trial application of Shanghai Fosun Pharmaceutical for the COVID-19 vaccine product candidate BNT162b1 (the “Vaccine”), in-licensed from BioNTech (BNTX +8.9%).
The Vaccine candidate is a prophylactic biological product, aiming at the precaution of COVID-19 for people who aged 18 or above.
In March 2020, Fosun Pharma obtained the license from BioNTech to jointly develop the vaccine in China.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.